Arthur Holden plans to leave his post as vice president of corporate and market development at Illumina in mid-October, the company said last week in a filing with the US Securities and Exchange Commission.
Holden is director of the Severe Adverse Events Consortium, a pharma-backed initiative that aims to find genetic causes for severe adverse events that hamper drug development.
Holden formerly was chairman and CEO of First Genetic Trust. He also served as chairman of the Pharmaceutical Biomedical Research Consortium and the DMD Translational Research Consortium, and as CEO of the SNP Consortium.
Shaf Yousaf has joined Applied Biosystems as president of the Molecular and Cell Biology Systems division. He joined ABI from Sigma-Aldrich, where he was president of the research biotech business unit.
In July, Applied Biosystems split its Molecular and Cell Division into two groups: MCB Systems and MCB Consumables.
At the time, Mark Stevenson, president of the Molecular and Cell Division, was promoted to executive vice president of the company. Peter Dansky heads the MCB Consumables group.
Harald Berninger has joined Kreatech Biotechnology as vice president of commercial operations. He replaces Rik van Heijningen, who left the company last month.
Berninger most recently served as director of life science, Asia for Qiagen. According to Kreatech, Berninger will now be responsible for all sales and marketing activities related to the firm’s Poseidon fluorescence in situ hybridization probe kits.
Current Kreatech product manager Dimitri Pappaioannou is now responsible for both the firm’s Poseidon probes and its array labeling kits, and Sandor Snoeijers will continue to serve as sales development manager for the worldwide development and support of Kreatech’s labeling solution activities.
Sharat Singh has been named senior vice president of research and development and Christopher Maki as vice president of worldwide sales at WaferGen Systems, the company said this week.
Singh joins the biochip firm from Aclara Biosciences where he served as chief scientific officer. Maki joins WaferGen following more than six years at Molecular Devices, now MDS Analytic Technologies, where he most recently served as the company's director of sales, research imaging and high-content screening.